scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Andrew J. Brooks | Q55155147 |
P2093 | author name string | Michael J Waters | |
P2860 | cites work | Stimulation of c-Src by prolactin is independent of Jak2. | Q42928957 |
Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation | Q43565424 | ||
Dimerization and signal transduction of the growth hormone receptor | Q44308491 | ||
Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways | Q44542433 | ||
Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation | Q45067684 | ||
An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. | Q46589328 | ||
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor | Q46713383 | ||
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity | Q47686615 | ||
Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications | Q50335953 | ||
Efficiency of signalling through cytokine receptors depends critically on receptor orientation | Q22003959 | ||
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex | Q24306425 | ||
Human growth hormone and extracellular domain of its receptor: crystal structure of the complex | Q24308045 | ||
Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation | Q24319880 | ||
The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation | Q24322589 | ||
Growth hormone receptor and serum binding protein: purification, cloning and expression | Q24339632 | ||
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 | ||
Crystal Structure of an Affinity-matured Prolactin Complexed to Its Dimerized Receptor Reveals the Topology of Hormone Binding Site 2 | Q27646645 | ||
An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor | Q27646869 | ||
Structural Organization of a Full-Length gp130/LIF-R Cytokine Receptor Transmembrane Complex | Q27652013 | ||
Structural Characterization of the Stem–Stem Dimerization Interface between Prolactin Receptor Chains Complexed with the Natural Hormone | Q27664687 | ||
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F | Q27670859 | ||
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition | Q27683852 | ||
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody | Q27694580 | ||
Activation of GH signaling and GH-independent stimulation of growth in zebrafish by introduction of a constitutively activated GHR construct. | Q51621525 | ||
gp130 activation is regulated by D2-D3 interdomain connectivity. | Q52633085 | ||
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. | Q54346714 | ||
Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations. | Q54479910 | ||
Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator. | Q54577274 | ||
Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full-length GH receptor | Q56936497 | ||
Role of the growth hormone–IGF-1 axis in cancer | Q57252658 | ||
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain | Q64008501 | ||
Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase | Q72796301 | ||
The role of receptor dimerization domain residues in growth hormone signaling | Q73067623 | ||
Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer | Q73739058 | ||
General classes and functions of four-helix bundle cytokines | Q77903163 | ||
The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling | Q79791774 | ||
Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor | Q81749177 | ||
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
The role of pacritinib in the management of myelofibrosis | Q87710103 | ||
Tofacitinib versus methotrexate in rheumatoid arthritis | Q88103514 | ||
Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A | Q27732820 | ||
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation | Q27766884 | ||
Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway | Q28269830 | ||
The growth hormone receptor: mechanism of activation and clinical implications | Q28289018 | ||
Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule | Q28609946 | ||
Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation | Q28637692 | ||
Structural design and molecular evolution of a cytokine receptor superfamily | Q29618154 | ||
Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. | Q30156952 | ||
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling | Q30406240 | ||
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase | Q30658298 | ||
Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263. | Q31153125 | ||
Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor | Q32079971 | ||
Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains | Q33231718 | ||
gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes | Q33246799 | ||
Evolution of Class I cytokine receptors | Q33291265 | ||
F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents | Q33388407 | ||
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor. | Q33530296 | ||
Binding in the growth hormone receptor complex | Q33593803 | ||
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses | Q33857008 | ||
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. | Q33909621 | ||
The molecular regulation of Janus kinase (JAK) activation | Q33956113 | ||
Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes | Q33967437 | ||
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation | Q34245259 | ||
The JAK/STAT signaling pathway | Q34305849 | ||
gp130 at the nexus of inflammation, autoimmunity, and cancer | Q34378756 | ||
Mechanism of activation of protein kinase JAK2 by the growth hormone receptor | Q34420222 | ||
Dynamic analysis of GH receptor conformational changes by split luciferase complementation | Q34422493 | ||
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure | Q34671755 | ||
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells | Q34698039 | ||
Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex | Q34712091 | ||
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. | Q34775393 | ||
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation | Q35043880 | ||
Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity | Q35134457 | ||
Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptor | Q36031581 | ||
Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity | Q36483460 | ||
Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. | Q36701486 | ||
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. | Q36776428 | ||
JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells | Q36826553 | ||
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders | Q36919975 | ||
A sequential dimerization mechanism for erythropoietin receptor activation | Q37353234 | ||
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms | Q37670068 | ||
Inhibition of IL-6 family cytokines by SOCS3. | Q37676036 | ||
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases | Q37687519 | ||
Prolactin regulation of the prostate gland: a female player in a male game | Q37942413 | ||
Lymphoid malignancies: Another face to the Janus kinases. | Q38075971 | ||
Signalling by the βc family of cytokines | Q38093731 | ||
Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy | Q38211431 | ||
Who climbs the tryptophan ladder? On the structure and function of the WSXWS motif in cytokine receptors and thrombospondin repeats | Q38214919 | ||
A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors | Q38237652 | ||
Profile of pacritinib and its potential in the treatment of hematologic disorders | Q38244524 | ||
Selective JAK inhibitors | Q38261371 | ||
Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation | Q38311941 | ||
An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia | Q38363447 | ||
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy | Q38824881 | ||
Lyn kinase plays important roles in erythroid expansion, maturation and erythropoietin receptor signalling by regulating inhibitory signalling pathways that control survival. | Q39022552 | ||
Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function | Q39126733 | ||
Orientation-specific signalling by thrombopoietin receptor dimers. | Q39592020 | ||
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain | Q39745564 | ||
The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor. | Q39893198 | ||
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. | Q40031223 | ||
Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation | Q40141599 | ||
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. | Q40357987 | ||
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer | Q40382202 | ||
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer | Q40613603 | ||
The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipper | Q40619204 | ||
Association of Lyn tyrosine kinase to the GM-CSF and IL-3 receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosis | Q40900402 | ||
Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization | Q40919215 | ||
The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor | Q40974112 | ||
Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. | Q41056199 | ||
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines | Q41075836 | ||
Functional replacement of cytokine receptor extracellular domains by leucine zippers | Q41149871 | ||
The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera | Q41185142 | ||
JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. | Q41197797 | ||
Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transduction | Q41347075 | ||
Rational design of potent antagonists to the human growth hormone receptor | Q41618965 | ||
Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex | Q41792413 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | membrane protein | Q423042 |
peptide | Q172847 | ||
cytokine | Q212354 | ||
enzyme | Q8047 | ||
cell surface receptor | Q2476074 | ||
hormone | Q11364 | ||
proto-oncogene protein | Q66020913 | ||
neoplasm protein | Q66894191 | ||
P1104 | number of pages | 11 | |
P304 | page(s) | 1-11 | |
P577 | publication date | 2015-02-15 | |
P1433 | published in | Biochemical Journal | Q864221 |
P1476 | title | JAK2 activation by growth hormone and other cytokines | |
P478 | volume | 466 |
Q52655332 | Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. |
Q36344846 | Binding of interferon reduces the force of unfolding for interferon receptor 1. |
Q92063512 | Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief |
Q57252653 | Cytokine Receptors |
Q91960810 | Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer's Disease |
Q38758497 | Defining human insulin-like growth factor I gene regulation |
Q46241287 | Diversification of the insulin-like growth factor 1 gene in mammals |
Q58555152 | Expression of the growth hormone receptor isoforms and its correlation with the metabolic profile in morbidly obese subjects |
Q40798911 | Fos-Zippered GH Receptor Cytosolic Tails Act as Jak2 Substrates and Signal Transducers |
Q90230800 | Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma |
Q52652594 | Growth hormone - past, present and future. |
Q42207921 | Growth hormone and insulin-like growth factor 1 affect the severity of Graves' disease |
Q52313979 | Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver. |
Q38671410 | Hepatic JAK2 protects against atherosclerosis through circulating IGF-1. |
Q38570383 | Immunological Consequences of JAK Inhibition: Friend or Foe? |
Q54114182 | Insulinlike Growth Factor 1 Gene Variation in Vertebrates. |
Q38781485 | Internalization and synaptogenic effect of GH in retinal ganglion cells (RGCs). |
Q45818945 | Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes |
Q26782539 | JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications |
Q92617002 | JAK2/STAT3 is associated with the inflammatory process in periapical granuloma |
Q38695289 | Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation. |
Q33884280 | Molecular interactions of EphA4, growth hormone receptor, Janus kinase 2, and signal transducer and activator of transcription 5B. |
Q92857474 | Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception |
Q89828211 | Molecular structure and function of Janus kinases: implications for the development of inhibitors |
Q41196669 | Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2. |
Q44159046 | Network-Based Method for Identifying Co- Regeneration Genes in Bone, Dentin, Nerve and Vessel Tissues. |
Q50516807 | Neuroprotection by GH against excitotoxic-induced cell death in retinal ganglion cells. |
Q42039904 | Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization |
Q56531947 | Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation |
Q90165530 | Regulation of gene expression by growth hormone |
Q98771847 | Structural Perspectives on Extracellular Recognition and Conformational Changes of Several Type-I Transmembrane Receptors |
Q61797690 | Targeting growth hormone function: strategies and therapeutic applications |
Q42801147 | The 20kDa and 22kDa forms of human growth hormone (hGH) exhibit different intracellular signalling profiles and properties |
Q51766789 | The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. |
Q38789207 | The New Genomics: What Molecular Databases Can Tell us About Human Population Variation and Endocrine Disease |
Q94555032 | The effects of growth hormone on therapy resistance in cancer |
Q92071391 | There and Back Again: A Cytokine Receptor's Tail |
Q26739716 | Ubc13: the Lys63 ubiquitin chain building machine |
Q28817460 | Zinc deficiency affects the STAT1/3 signaling pathways in part through redox-mediated mechanisms |
Search more.